Trial site
Knoxville
Knoxville, Tennessee 37920, United StatesNot linked to an institution yet
- 16running trials
- 14closed trials
The trials here
What the 30 trials at this site are about, from their registry records.
- Phase
- Phase 319 trials
- Phase 27 trials
- Phase 42 trials
- Phase 2/31 trial
- Status
- Completed10 trials
- Recruiting7 trials
- Active, not recruiting5 trials
- Not yet recruiting4 trials
- Terminated2 trials
- Withdrawn2 trials
- Lead sponsor
- AstraZeneca26 trials
- Alexion Pharmaceuticals, Inc.2 trials
- Biogen1 trial
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics1 trial
Running trials
Recruiting
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
NCT07784270· Phase 3· AstraZeneca· Source
Recruiting
A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.
NCT07619131· Phase 3· AstraZeneca· Source
Recruiting
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus
NCT07662044· Phase 3· AstraZeneca· Source
Recruiting
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
NCT07667803· Phase 3· AstraZeneca· Source
Recruiting
An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.
NCT07357597· Phase 4· AstraZeneca· Source
Recruiting
A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab
NCT07221838· Phase 4· Alexion Pharmaceuticals, Inc.· Source
Contact: Alexion Pharmaceuticals, Inc. (Sponsor)
Recruiting
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
NCT07044336· Phase 3· AstraZeneca· Source
Recruiting
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
NCT06878261· Phase 3· AstraZeneca· Source
Recruiting
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
NCT06742723· Phase 3· AstraZeneca· Source
Recruiting
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
NCT06764875· Phase 3· AstraZeneca· Source
Active, not recruiting
A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features
NCT06564844· Phase 3· AstraZeneca· Source
Recruiting
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
NCT06307652· Phase 3· AstraZeneca· Source
Active, not recruiting
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT06291376· Phase 3· Alexion Pharmaceuticals, Inc.· Source
Active, not recruiting
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
NCT04960709· Phase 3· AstraZeneca· Source
Active, not recruiting
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer
NCT04269200· Phase 3· AstraZeneca· Source
Active, not recruiting
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
NCT03330847· Phase 2· AstraZeneca· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error